Abstract
We present a case of foscarnet (FOS) resistance arising from a UL54 mutation after a short duration of FOS exposure, which has not been previously described in a stem cell transplant recipient, to our knowledge. We discuss the use of FOS to treat other viral infections and the implications this may have for the development of resistance mutations and treatment of cytomegalovirus disease.
Keywords:
E756K mutation; UL54; cytomegalovirus; foscarnet; resistance.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
MeSH terms
-
Antiviral Agents / therapeutic use*
-
Cidofovir
-
Cytomegalovirus / genetics*
-
Cytomegalovirus Infections / drug therapy*
-
Cytosine / analogs & derivatives
-
Cytosine / therapeutic use
-
DNA-Directed DNA Polymerase / genetics*
-
Drug Resistance, Viral / genetics*
-
Foscarnet / therapeutic use*
-
Ganciclovir / therapeutic use
-
Hematopoietic Stem Cell Transplantation / adverse effects*
-
Humans
-
Male
-
Middle Aged
-
Mutation
-
Organophosphonates / therapeutic use
-
Viral Proteins / genetics*
Substances
-
Antiviral Agents
-
Organophosphonates
-
UL54 protein, Human herpesvirus 5
-
Viral Proteins
-
Foscarnet
-
Cytosine
-
DNA-Directed DNA Polymerase
-
Cidofovir
-
Ganciclovir